ImmunoGen, Inc.
IMGN
Clasificación en acciones
#2965
ImmunoGen, Inc. is a clinical-stage biotechnology enterprise that specializes... ImmunoGen, Inc. is a clinical-stage biotechnology enterprise that specializes in the creation of antibody-drug conjugate (ADC) therapies for cancer treatment. A prominent drug in their pipeline is mirvetuximab soravtansine, an ADC designed to target folate-receptor alpha (FRa), which is currently undergoing Phase III clinical trials for patients with platinum-resistant ovarian cancer. Another significant candidate, Pivekimab sunirine, a CD123-targeting ADC, is progressing through Phase II studies for acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Beyond its clinical efforts, the company's preclinical portfolio includes IMGC936, an ADC being co-developed with MacroGenics, Inc., and IMGN151, another anti-FRa therapeutic. ImmunoGen maintains strategic collaborations with a range of key industry players, such as Roche, Amgen/Oxford BioTherapeutics, Bayer HealthCare AG, Eli Lilly and Company, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Fusion Pharmaceuticals Inc., Debiopharm International SA, and MacroGenics, Inc. Founded in 1980, ImmunoGen, Inc. is headquartered in Waltham, Massachusetts.
Precio por acción
$31.23
Última sincronización: 2024-02-13
Capitalización bursátil
$6.24B
Cambio (1 día)
0.00%
Cambio (1 año)
-0.03%
País
US
Comercio ImmunoGen, Inc. (IMGN)
Categoría
Healthcare
Historial de desdoblamientos de acciones de ImmunoGen, Inc. (IMGN)
La acción ImmunoGen, Inc. (símbolo: IMGN) tuvo un total de 0 desdoblamientos.
El desdoblamiento más reciente ocurrió el Oct 21, 2026.
Una acción IMGN comprada antes de Oct 21, 2026 equivaldría hoy a 0 acciones IMGN.
El desdoblamiento más reciente ocurrió el Oct 21, 2026.
Una acción IMGN comprada antes de Oct 21, 2026 equivaldría hoy a 0 acciones IMGN.
Lista de desdoblamientos de acciones
| Año | Desdoblamiento | Multiplicador | Multiplicador acumulado |
|---|---|---|---|
| Not enough data for the provided dates. | |||
Desdoblamientos de acciones de empresas similares o competidoras
| Empresa | Número de desdoblamientos de acciones | Multiplicador acumulado | País |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|